Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group

According to the results of a pre-specified futility analysis of the phase IIb RuxoBEAT trial, previously untreated patients with PV who received ruxolitinib experienced a significant reduction in median hematocrit (46% to 41%), in the median number of phlebotomies per year (4.0 to 0), and in median patient-reported pruritus scores (2 to 1), as well as reduced night sweat scores (1.5 to 0).